Kitov receives FDA 510(k) clearance for osteoarthritis pain, hypertension medication: 3 insights

Biopharmaceutical company Kitov received FDA 510(k) clearance for its Consensi oral tablets for the treatment of osteoarthritis pain and hypertension.

Advertisement

Here are three things to know:

1. Consensi is a patent-protected combination of the non-steroidal anti-inflammatory drug celecoxib and amlodipine besylate, an antihypertensive calcium channel blocker.

2. It is indicated for patients for whom amlodipine treatment for hypertension and celecoxib treatment for osteoarthritis are appropriate.

3. According to Kitov’s founder and CMO J. Paul Waymack, MD, the company will now focus on NT219, an investigational new drug candidate currently in development for several oncology indications.

More articles on orthopedics:

Dr. Leslie Dean retires: 3 things to know

Orthopedic surgeon to know: Dr. James Carson of Cypress Fairbanks Medical Center Hospital

Drs. Paul Pellici, Craig Miller & more: 4 orthopedic surgeons making headlines

At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.

Register to Attend Webinar

160 ambulatory leaders just ranked the EHR as the single system most overdue for AI reinvention

Tuesday, August 11
12:00 PM - 1:00 PM CDT

Presenter: Gautam Shah, MBA, FACHDM, NextGen Healthcare

Advertisement

Next Up in Orthopedic

Advertisement

Comments are closed.